FDA Accepts Satraplatin NDA and Grants Priority Review
Spectrum Pharmaceuticals, Inc, recently announced that the New Drug Application (NDA) for satraplatin has been accepted for priority review by the US Food and Drug Administration (FDA). A Prescription Drug User Fee Act date of August 15, 2007, has been established by the FDA for a decision regarding the approval of the satraplatin application. Satraplatin is an investigational drug for the treatment of hormone-refractory prostate cancer in patients who have failed prior chemotherapy.
Spectrum Pharmaceuticals, Inc, recently announced that the New Drug Application (NDA) for satraplatin has been accepted for priority review by the US Food and Drug Administration (FDA). A Prescription Drug User Fee Act date of August 15, 2007, has been established by the FDA for a decision regarding the approval of the satraplatin application. Satraplatin is an investigational drug for the treatment of hormone-refractory prostate cancer in patients who have failed prior chemotherapy.
!["Policy changes aimed at supporting and more broadly enabling breastfeeding, addressing structural barriers, and promoting a culture shift could reduce overall incidence and racial disparities in TNBC incidence in the [US]," according to the study authors.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fc33b85fa4b3edf9bdd0a6d37d81eee57f71a7348-1200x960.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "\"Policy changes aimed at supporting and more broadly enabling breastfeeding, addressing structural barriers, and promoting a culture shift could reduce overall incidence and racial disparities in TNBC incidence in the [US],\" according to the study authors.")
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
